Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Sonlicromanol

Source date not recordedAnalyse record ↗

Investigational redox modulator in Phase 3 for m.3243A>G-related primary mitochondrial disease.

Modality
oral brain-penetrant redox-modulating small molecule
Availability (US)
Phase 3 KHENERFIN; first participant dosed April 16, 2026; investigational and not approved
Biomarkers
fatigue; muscle weakness; redox homeostasis; inflammatory and ferroptosis-related measures
Hallmark targeted
mitochondrial dysfunction, oxidative stress, chronic inflammation
Kind
investigational drug
Clinical trials
NCT06451757 — KHENERFIN randomized placebo-controlled Phase 3 study in adults with m.3243A>G primary mitochondrial disease